Johnson & Johnson (NYSE:JNJ) Shares Bought by Fi3 FINANCIAL ADVISORS LLC

Key Points

• Fi3 Financial Advisors LLC boosted its stake in Johnson & Johnson by 71.6%, holding 4,680 shares worth approximately $776,000 as of the latest SEC filing.
• Johnson & Johnson reported $2.77 earnings per share for the last quarter, beating estimates of $2.68, and had revenue of $23.74 billion, surpassing analyst expectations.
• The company declared a quarterly dividend of $1.30 per share, representing an annual yield of 3.0%, with a dividend payout ratio of 55.61%.

Fi3 FINANCIAL ADVISORS LLC grew its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 71.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,680 shares of the company's stock after acquiring an additional 1,952 shares during the period. Fi3 FINANCIAL ADVISORS LLC's holdings in Johnson & Johnson were worth $776,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Bernard Wealth Management Corp. acquired a new stake in shares of Johnson & Johnson during the 4th quarter valued at approximately $36,000. Highline Wealth Partners LLC lifted its position in shares of Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after acquiring an additional 86 shares during the period. von Borstel & Associates Inc. acquired a new stake in shares of Johnson & Johnson during the 1st quarter valued at approximately $49,000. Harvest Fund Management Co. Ltd acquired a new stake in shares of Johnson & Johnson during the 1st quarter valued at approximately $52,000. Finally, Capital A Wealth Management LLC acquired a new stake in shares of Johnson & Johnson during the 4th quarter valued at approximately $50,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on JNJ shares. Benchmark upgraded shares of Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Leerink Partners downgraded shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and reduced their price target for the company from $169.00 to $153.00 in a report on Tuesday, May 13th. Guggenheim reaffirmed a "neutral" rating and issued a $167.00 price target (up previously from $164.00) on shares of Johnson & Johnson in a report on Thursday, July 17th. Wall Street Zen downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a report on Friday, July 18th. Finally, Piper Sandler reaffirmed an "overweight" rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Nine research analysts have rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $174.50.

Johnson & Johnson Trading Up 1.1%

JNJ stock traded up $1.87 on Friday, hitting $173.40. 7,686,049 shares of the company were exchanged, compared to its average volume of 9,496,232. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $173.96. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The business's fifty day moving average is $159.26 and its two-hundred day moving average is $157.44. The stock has a market capitalization of $417.61 billion, a price-to-earnings ratio of 18.55, a price-to-earnings-growth ratio of 2.18 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business's quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the company earned $2.82 EPS. As a group, research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is presently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.